2126 Stock Overview
A clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of cellular immunotherapy products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
JW (Cayman) Therapeutics Co. Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.73 |
| 52 Week High | HK$2.48 |
| 52 Week Low | HK$1.19 |
| Beta | 2.12 |
| 1 Month Change | 7.45% |
| 3 Month Change | -28.22% |
| 1 Year Change | -23.45% |
| 3 Year Change | -75.14% |
| 5 Year Change | n/a |
| Change since IPO | -92.14% |
Recent News & Updates
Market Cool On JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Revenues Pushing Shares 37% Lower
Apr 08
Market Might Still Lack Some Conviction On JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even After 37% Share Price Boost
Feb 12Recent updates
Market Cool On JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Revenues Pushing Shares 37% Lower
Apr 08Market Might Still Lack Some Conviction On JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even After 37% Share Price Boost
Feb 12Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper
Nov 12JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch
Sep 25A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb
May 10Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
May 03JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?
Feb 03Shareholder Returns
| 2126 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 3.6% | 10.1% | 1.8% |
| 1Y | -23.5% | 72.3% | 16.9% |
Return vs Industry: 2126 underperformed the Hong Kong Biotechs industry which returned 72.3% over the past year.
Return vs Market: 2126 underperformed the Hong Kong Market which returned 16.9% over the past year.
Price Volatility
| 2126 volatility | |
|---|---|
| 2126 Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 13.4% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2126's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2126's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 281 | Min Liu | www.jwtherapeutics.com |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for the treatment of a range of hematological cancers, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease.
JW (Cayman) Therapeutics Co. Ltd Fundamentals Summary
| 2126 fundamental statistics | |
|---|---|
| Market cap | HK$701.28m |
| Earnings (TTM) | -HK$644.14m |
| Revenue (TTM) | HK$172.56m |
Is 2126 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2126 income statement (TTM) | |
|---|---|
| Revenue | CN¥158.22m |
| Cost of Revenue | CN¥80.90m |
| Gross Profit | CN¥77.32m |
| Other Expenses | CN¥667.94m |
| Earnings | -CN¥590.62m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 48.87% |
| Net Profit Margin | -373.30% |
| Debt/Equity Ratio | 32.6% |
How did 2126 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/24 17:57 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JW (Cayman) Therapeutics Co. Ltd is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Tony Ren | CLSA |